ライフサイエンスコーパス: Abbott

1 l were 19% (Monitor), 22% (TaqMan), and 25% (Abbott).

2 A new rapid test, Determine (Abbott, Abbott Park, Ill.), detects HIV type 1 (HIV-1) a

3 cquired immunodeficiency syndrome, Bragdon v Abbott, addressed this trend by ruling that a woman with

4 agNA Pure LC instrument (Roche RUO-MPLC) and Abbott analyte-specific reagents (ASR) with QIAGEN sampl

5 d with sensitivities of 89.1 and 60% for the Abbott and CBC (previously DuPont) kits, respectively, l

6 Abbott and Gen-Probe confirmed discrepant results by alt

7 obtained from plasma specimens tested by the Abbott and QIAGEN tests were in very close agreement (me

8 that the sensitivity and linear range of the Abbott and Roche RT-PCR assays enable them to be used fo

9 ott RealTime HIV-1 test on the m2000 system (Abbott), and the Roche TaqMan HIV-1 test, v2.0 (TaqMan).

10 genotyping methodologies supplied by Bayer, Abbott, and Third Wave Technologies.

11 hsTnI was measured using the Abbott ARCHITECT assay at baseline and 6 months in patie

12 Studies for the Abbott ARCHITECT HCV Ag assay had the highest quality, w

13 of circulating high-sensitivity troponin I (Abbott ARCHITECT), with acute respiratory distress syndr

14 d specificity of the assays were as follows: Abbott ARCHITECT, 93.4% (95% CI, 90.1% to 96.4%) and 98.

15 In 3 quantitative studies using Abbott ARCHITECT, HCVcAg correlated closely with HCV RNA

16 tion was obtained for the Roche RUO-MPLC and Abbott ASR-Q (R(2) = 0.84 and R(2) = 0.93, respectively)

17 stems showed acceptable reproducibility, the Abbott ASR-Q being the most reproducible of the three sy

18 r study demonstrates that Roche RUO-MPLC and Abbott ASR-Q provided acceptable results and agreed suff

19 eagents (ASR) with QIAGEN sample processing (Abbott ASR-Q) showed a sensitivity of 1.0 log(10) IU/ml

20 respectively), with better agreement for the Abbott ASR-Q.

21 en the two assays, which is given as log(10) Abbott assay measure = 0.032 + 1.01 log(10) Bayer assay

22 h correlation between the Xpert HIV-1 VL and Abbott assay results (r(2) = 0.92; P < 0.001).

23 re appeared to be an enhanced ability of the Abbott assay to detect dual infections, especially in th

24 values obtained by Xpert HIV-1 VL assay and Abbott assay was 0.34 log10 copies/ml (95% confidence in

25 hs-cTnI was measured (Abbott assay) using sex-specific 99th percentiles (women

26 boratory-based Abbott m2000sp/m2000rt assay (Abbott assay).

27 By the Abbott assay, 90% (53/59) had HCV RNA <LLOQ, of whom 1 p

28 sults by the participants were 96.6% for the Abbott assay, 96.3% for the Roche Cobas assay, 94.5% for

29 r assay, and only 77 of 137 specimens by the Abbott assay.

30 Both the POC Xpert HIV-1 VL and Abbott assays were performed on specimens sampled from 2

31 in had HCV RNA <LLOQ at EOT by the Roche and Abbott assays, but only 38 achieved SVR12 (PPV, 69%).

32 echnologies, the AMP CT (Gen-Probe) and LCx (Abbott) assays.

33 ic emptying (scintigraphy, 100 mL of Ensure (Abbott Australia, Kurnell, Australia) with 20 MBq Tc-sup

34 oglobulin M (IgM) test, was developed on the Abbott AxSYM analyzer.

35 ormance of the new recombinant antigen-based Abbott AxSYM CMV IgM assay and compared it with CMV cult

36 ese results show that the sensitivity of the Abbott C. trachomatis LCR test is affected by the presen

37 We report the use of adalimumab (Abbott, Canada, Inc.) for orbital myositis in a patient

38 V (Fisher Scientific, Hanover Park, IL), and Abbott CMV (Abbott Park, IL).

39 s (50 from Utah Medical Products and 50 from Abbott Critical Care Systems [25 new, 25 clinically used

40 In this issue of Neuron, Sussillo and Abbott describe a new learning rule that helps harness t

41 ing; those who accepted were tested with the Abbott Determine and Trinity Biotech Capillus SR tests i

42 Both antibodies are used in Abbott diagnostic assays on AxSYM, IMx, and Architect pl

43 Behring Diagnostics OPUS Toxo G and Toxo M, Abbott Diagnostics IMX Toxo-IgG 2.0 and Toxo-IgM, Sanofi

44 Architect HIV Ag/Ab Combo [HIV Combo] assay; Abbott Diagnostics) in 2,744 HIV antibody-negative sampl

45 was measured with a high-sensitivity assay (Abbott Diagnostics, Abbott Park, IL).

46 of the 1988 versions, the specificity of the Abbott EIA has decreased and the specificity of the CBC

47 cordance between the Ortho/ECi assay and the Abbott EIA were 97.78, 93.54, and 97.66% for anti-HCV an

48 ormance, six groups of sera prescreened with Abbott EIAs were assayed: anti-HCV-negative samples (n =

49 esting of the 200 prospective specimens, the Abbott, Elitech, EraGen, and Focus PCR assays demonstrat

50 The Abbott, EraGen, Elitech, Focus, and LDT PCR assays perfo

51 a DC to bathing [K+] in desheathed nerves of Abbott et al.

52 ified using average surface roughness Ra and Abbott-Firestone curves.

53 ily); 13 (57%), were serum HBV DNA positive (Abbott Genostics, Abbott Laboratories, Chicago, IL) at s

54 Current diagnostic assays, such as the Abbott HAVAB test, used to determine exposure to HAV det

55 The Abbott HBV RUO Sequencing assay (Abbott Molecular Inc.,

56 The Abbott HBV RUO Sequencing assay provided a convenient an

57 e Trugene HBV Genotyping kit (n = 7) and the Abbott HBV RUO Sequencing assay showed minor differences

58 RNA (version 3.0) branched DNA assay and the Abbott HCV analyte-specific reagent real-time PCR assay,

59 have recently become commercially available (Abbott HCV Genotype ASR).

60 ested by a licensed enzyme immunoassay (EIA; Abbott HIV-1) and Western blot assay (Cambridge-Biotech)

61 e high-sensitivity (hs) cTn assays (hs-cTnI, Abbott; hs-cTnT, Roche) among 2300 consecutive patients

62 s: CDC EIA IgM, 100 and 99.1%, respectively; Abbott IMx Toxo IgM, version 1, 100 and 77.5%, respectiv

63 IgM, version 1, 100 and 77.5%, respectively; Abbott IMx Toxo IgM, version 2, 93.3 and 97.3%, respecti

64 As a model system, we chose the Abbott IMx Toxo immunoglobulin M (IgM) and Toxo IgG assa

65 HM3 LVAS with the HeartMate II (HMII) LVAS (Abbott) in advanced heart failure refractory to medical

66 demonstrates that, consistent with Bragdon v Abbott, individuals with asymptomatic HIV have widesprea

67 and the LCx nucleic acid amplification test (Abbott Industries, Abbott Park, Ill.).

68 rdance of viral genotype quantitation of the Abbott investigational use only RealTime HCV (RealTime)

69 (HM3) Left Ventricular Assist System (LVAS) (Abbott) is a centrifugal, fully magnetically levitated,

70 (CBC), and two from Abbott Laboratories (the 1993 modification [Abb 93] and

71 Drug discovery efforts at Abbott Laboratories have led to the identification of in

72 problems can occur during routine use of the Abbott Laboratories LCx assay for Chlamydia trachomatis

73 mples with discordant results were tested by Abbott Laboratories Micro-Particle Immunoassay (M-EIA) a

74 Recent efforts from the Abbott Laboratories resulted in the development of the a

75 Diagnostics) and ligase chain reaction LCR (Abbott laboratories) and compared three PCR specimen-pro

76 d compared with an enzyme immunoassay (EIA) (Abbott Laboratories) licensed by the Food and Drug Admin

77 stics) and antigen detection (Chlamydiazyme; Abbott Laboratories) performed on the same women.

78 obe System Chlamydia trachomatis Assay (LCx; Abbott Laboratories), the APTIMA Combo 2 Assay (AC2; Gen

79 tion obtained by ligase chain reaction (LCR; Abbott Laboratories).

80 or the ETA/B, A-182086, receptor antagonist (Abbott Laboratories, Abbott Park, IL) directly to the pr

81 nty Wicklow, Ireland) and Determine HIV-1/2 (Abbott Laboratories, Abbott Park, IL) rapid tests in a r

82 anti-HCV with confirmation with Matrix 2.0 (Abbott Laboratories, Abbott Park, IL), and reverse trans

83 enzimidazole-4-carboxamide, dihydrochloride; Abbott Laboratories, Abbott Park, IL), and the DNA-damag

84 d.) and influenza A virus (Abbott Test Pack; Abbott Laboratories, Abbott Park, Ill.) for the detectio

85 The Abbott LCx Neisseria gonorrhoeae assay (Abbott Laboratories, Abbott Park, Ill.) uses a ligase ch

86 Ligase chain reaction (LCR) (Abbott Laboratories, Abbott Park, Ill.) with first-catch

87 determined by the Auszyme Monoclonal assay (Abbott Laboratories, Abbott Park, Ill.), was 0.56% (39 o

88 ifferent enzyme-linked immunosorbent assays (Abbott Laboratories, Abbott Park, Ill.; Embrabio, Sao Pa

89 ed (ligase chain reaction [LCx Probe System; Abbott Laboratories, Abbott Park, Ill.]; PCR [Amplicor;

90 ter-based leaflet repair with the MitraClip (Abbott Laboratories, Abbott Park, Illinois) is accomplis

91 Absorb Bioresorbable Vascular Scaffold 1.1 (Abbott Laboratories, Abbott Park, Illinois).

92 titutes of Health, University of California, Abbott Laboratories, and the Centers for Disease Control

93 re serum HBV DNA positive (Abbott Genostics, Abbott Laboratories, Chicago, IL) at study entry.

94 on in the LCx Chlamydia assay (LCx-CT assay; Abbott Laboratories, Chicago, Ill.) by using a commercia

95 d with the extended-release niacin (Niaspan, Abbott Laboratories, Chicago, Illinois, USA).

96 Abbott Laboratories, Genentech, and National Cancer Inst

97 tional Cancer Institute, Sanofi-Aventis, and Abbott Laboratories.

98 PRIMARY FUNDING SOURCE: Abbott Laboratories.

99 , Gilead Sciences, Boehringer-Ingelheim, and Abbott Laboratories.

100 ction in urine samples with three NAATs: the Abbott LCx (LCx), BD ProbeTec ET (ProbeTec), and Gen-Pro

101 The Abbott LCx assay is a rapid, sensitive method for detect

102 cially available HIV RNA quantitative tests: Abbott LCx HIV RNA Quantitative assay (LCx), Bayer Versa

103 The Abbott LCx ligase chain reaction (LCR) assay for the sim

104 ter normal laboratory sputum processing, the Abbott LCx MTB Assay can be completed in 6 h.

105 Results from the LCR assay (Abbott LCx Mycobacterium tuberculosis [MTB] Assay) were

106 The Abbott LCx Neisseria gonorrhoeae assay (Abbott Laborator

107 catch urine [FCU]) initially positive by the Abbott LCx Probe System Chlamydia trachomatis Assay (LCx

108 icile toxin genes, the IMDx C. difficile for Abbott m2000 Assay (IMDx) and the BD Max Cdiff Assay (Ma

109 only RealTime HCV (RealTime) assay using the Abbott m2000 platform and compared the results to those

110 This assay is designed to be performed on an Abbott m2000 real-time instrument system, which consists

111 he GeneXpert CT/NG assay (GeneXpert) and the Abbott m2000 RealTime CT (m2000) assay were compared to

112 pliPrep/COBAS TaqMan HIV-1 v.2 (CAP/CTM) and Abbott m2000 RealTime HIV-1 (RealTime) assays on all sub

113 PVLs were measured using Abbott m2000rt real-time polymerase chain reaction, and

114 HIV-1 VL assay against the laboratory-based Abbott m2000sp/m2000rt assay (Abbott assay).

115 sma samples from 40 patients enrolled in the Abbott M97-720 trial at baseline (pretherapy) and weeks

116 second laser-enabled (150-kHz IntraLase iFS; Abbott Medical Optics Inc) wavefront-guided ablation.

117 OL (one-piece Tecnis-1 or three-piece AR40E, Abbott Medical Optics Inc.) had been previously placed.

118 us ultrasound on transverse ultrasound using Abbott Medical Optics' (AMO) WhiteStar Signature Pro wit

119 (Alcon Laboratories), or Tecnis Multifocal (Abbott Medical Optics) lenses.

120 The AMO WhiteStar Signature Pro machine (Abbott Medical Optics) with the Ellips FX handpiece and

121 x CustomVue Star S4 IR excimer laser system; Abbott Medical Optics), and the fellow eye received WFO

122 ide cut made with the 150 kHz IntraLase iFS (Abbott Medical Optics).

123 (GDD) surgery (Baerveldt 350, Baerveldt 250 [Abbott Medical Optics, Abbott Park, IL], or Ahmed FP7 [N

124 A Signature (Abbott Medical Optics, Inc) phacoemulsification machine

125 o Cucamonga, CA) or a Baerveldt-350 implant (Abbott Medical Optics, Inc, Santa Ana, CA) using a stand

126 o Cucamonga, CA) or a Baerveldt-350 implant (Abbott Medical Optics, Inc., Santa Ana, CA) using a stan

127 created using the Catalys femtosecond laser (Abbott Medical Optics, Inc., Santa Ana, CA).

128 Tecnis ZM900 diffractive multifocal lenses (Abbott Medical Optics, Santa Ana, CA) or Akreos AO monof

129 side cut made with the 60 kHz IntraLase FS (Abbott Medical Optics, Santa Ana, CA) or an inverted 130

130 ere created using the 150-kHz IntraLase iFS (Abbott Medical Optics, Santa Ana, CA).

131 Texas, USA), or Tecnis +4D Multifocal (MF) (Abbott Medical Optics, Santa Ana, California, USA) IOL.

132 d to percutaneous repair with the MitraClip (Abbott, Menlo Park, California) device or conventional m

133 l valve with a particular device (MitraClip, Abbott, Menlo Park, California) has emerged as a novel t

134 ive nonculture tests included Chlamydiazyme (Abbott), MicroTrak direct fluorescent antibody (DFA) (Sy

135 One version is distributed by Abbott Molecular and the other by QIAGEN.

136 matis and Neisseria gonorrhoeae developed by Abbott Molecular Inc.

137 The PLEX-ID Flu assay (Abbott Molecular Inc., Des Plaines, IL) incorporates mul

138 The Abbott HBV RUO Sequencing assay (Abbott Molecular Inc., Des Plaines, IL), which combines

139 ultures; the Ibis T5000 universal biosensor (Abbott Molecular); and 16S 454 FLX titanium series pyros

140 FISH was performed using UroVysion (Abbott Molecular, Inc, Des Plaines, IL) and classified a

141 The introduction of the Abbott mPLUS feature, with the capacity for extended use

142 me-linked immunosorbent assay (ELISA) tests (Abbott Murex HIV Ag/Ab combination and Vironostika Unifo

143 he ambulatory Minneapolis Heart Institute at Abbott Northwestern Hospital.

144 6, receptor antagonist (Abbott Laboratories, Abbott Park, IL) directly to the preservation solution (

145 and Determine HIV-1/2 (Abbott Laboratories, Abbott Park, IL) rapid tests in a reference laboratory u

146 mation with Matrix 2.0 (Abbott Laboratories, Abbott Park, IL), and reverse transcriptase-polymerase c

147 amide, dihydrochloride; Abbott Laboratories, Abbott Park, IL), and the DNA-damaging topoisomerase I i

148 high-sensitivity assay (Abbott Diagnostics, Abbott Park, IL).

149 ientific, Hanover Park, IL), and Abbott CMV (Abbott Park, IL).

150 t 350, Baerveldt 250 [Abbott Medical Optics, Abbott Park, IL], or Ahmed FP7 [New World Medical Inc, R

151 irus (Abbott Test Pack; Abbott Laboratories, Abbott Park, Ill.) for the detection of respiratory viru

152 eria gonorrhoeae assay (Abbott Laboratories, Abbott Park, Ill.) uses a ligase chain reaction (LCR) am

153 e chain reaction (LCR) (Abbott Laboratories, Abbott Park, Ill.) with first-catch urine specimens was

154 A new rapid test, Determine (Abbott, Abbott Park, Ill.), detects HIV type 1 (HIV-1) and HIV-2

155 szyme Monoclonal assay (Abbott Laboratories, Abbott Park, Ill.), was 0.56% (39 of 6,986 repeatedly re

156 acid amplification test (Abbott Industries, Abbott Park, Ill.).

157 d immunosorbent assays (Abbott Laboratories, Abbott Park, Ill.; Embrabio, Sao Paulo, Brazil; Organon

158 tion [LCx Probe System; Abbott Laboratories, Abbott Park, Ill.]; PCR [Amplicor; Roche Molecular Syste

159 using the MitraClip device (Abbott Vascular, Abbott Park, Illinois) and compare the results with surg

160 olimus-eluting stent (EES) (Abbott Vascular, Abbott Park, Illinois) in the RESOLUTE (A Randomized Com

161 air with the MitraClip (Abbott Laboratories, Abbott Park, Illinois) is accomplished with an implantab

162 Vascular Scaffold 1.1 (Abbott Laboratories, Abbott Park, Illinois).

163 says and 0.96 (95% CI, 0.90 to 0.98) for the Abbott Qualitative assay.

164 (95% CI, 0.97 to 1.00) for the AmpliSens and Abbott Qualitative assays and 0.99 (95% CI, 0.96 to 1.00

165 NA not detected (RNA(-)), as measured by the Abbott Real Time assay.

166 echnical and clinical feasibility of the new Abbott real-time PCR C. trachomatis/N. gonorrhoeae assay

167 We evaluated the Abbott RealTime (ART) and Roche Cobas TaqMan Hepatitis C

168 ng the High Pure System and reanalyzed using Abbott RealTime (limits of detection, 15.1 IU/ml versus

169 The Abbott RealTime (RT) HCV assay targets the 5' untranslat

170 of the patients with undetectable HCV RNA by Abbott RealTime achieved a sustained virologic response.

171 le HCV RNA as the cutoff, the more sensitive Abbott RealTime assay would identify fewer patients elig

172 eviously established in other studies of the Abbott RealTime assay, to determine eligibility for shor

173 oofer (NorChip), Aptima HPV (Gen-Probe), and Abbott RealTime assays, the BD HPV test, and CINtec p16(

174 nce characteristics of the newly FDA-cleared Abbott RealTime CT/NG assay (where "CT" stands for Chlam

175 In summary, we conclude that the Abbott RealTime CT/NG assay is an accurate and automated

176 The Abbott RealTime CT/NG assay offers C. trachomatis and N.

177 e overall sensitivity and specificity of the Abbott RealTime CT/NG assay were 92.4% and 99.2% for C.

178 luate the performance characteristics of the Abbott RealTime CT/NG assay, a multiplex real-time PCR a

179 Specimens were tested with the automated Abbott RealTime CT/NG assay, Aptima Combo 2 assay (Gen-P

180 Abbott RealTime had 93.3% sensitivity, 27.3% specificity

181 The Abbott RealTime HBV assay targets the N-terminal region

182 fined as HBV DNA levels >15 IU/mL, using the Abbott RealTime HBV DNA assay.

183 irus (HBV) quantification were assessed: the Abbott RealTime HBV IUO, the Roche Cobas AmpliPrep/Cobas

184 s, Cobas AmpliPrep/CobasTaqMan (CAP/CTM) and Abbott RealTime HCV (ART) assays.

185 sults were compared to quantification by the Abbott RealTime HCV assay.

186 hich was also similarly misquantified by the Abbott RealTime HCV assay.

187 rt HCV Viral Load assay in comparison to the Abbott RealTime HCV assay.

188 sing the Roche COBAS TaqMan HCV test and the Abbott RealTime HCV assay.

189 The Abbott RealTime HCV Genotype II RUO (research use only)

190 the Roche High Pure System/Cobas TaqMan and Abbott RealTime HCV RNA assays and the impacts of differ

191 red to those tested retrospectively with the Abbott RealTime HCV RNA test (ART).

192 uncture and finger-stick collection with the Abbott RealTime HCV Viral Load assay (gold standard).

193 1 v1.5 (n = 25), Cobas TaqMan v2.0 (n = 11), Abbott RealTime HIV-1 (n = 23), Versant HIV-1 RNA bDNA 3

194 pliPrep/Cobas TaqMan HIV-1 test (RT) and the Abbott RealTime HIV-1 assay (AR), that utilize real-time

195 curacy of HIV-1 viral load results using the Abbott RealTime HIV-1 assay and (ii) evaluate the effect

196 discordant results were observed between the Abbott RealTime HIV-1 assay and the COBAS AmpliPrep/COBA

197 HIV-1 Quant Dx assay in comparison with the Abbott RealTime HIV-1 assay using plasma and cervicovagi

198 ect on viral load results as measured by the Abbott RealTime HIV-1 assay.

199 accurate quantification of HIV-1 RNA in the Abbott RealTime HIV-1 assay.

200 this design strategy was demonstrated in the Abbott RealTime HIV-1 assay.

201 70% of results from the Versant bDNA 3.0 and Abbott RealTime HIV-1 differed by greater than 0.5log10.

202 negative specimens were also tested with the Abbott RealTime HIV-1 Qual assay (RealTime).

203 AS TaqMan (CAP/CTM) HIV-1 Qual test, and the Abbott RealTime HIV-1 Qualitative assay.

204 Roche Amplicor Monitor, v1.5 (Monitor), the Abbott RealTime HIV-1 test on the m2000 system (Abbott),

205 plicor Monitor v1.5 showed a tendency of the Abbott RealTime HIV-1 to under-estimate results while th

206 The Abbott RealTime HIV-1 viral load assay uses primers and

207 erage intra and inter-assay variation of the Abbott RealTime HIV-1 were 2.95% (range 2.0-5.1%) and 5.

208 Bias data comparing the Abbott RealTime HIV-1, TaqMan v2.0 to the Amplicor Monit

209 The Abbott RealTime human immunodeficiency virus type 1 (HIV

210 nly) assay was evaluated using the automated Abbott RealTime m2000 system.

211 The Abbott RealTime MTB assay is a nucleic acid amplificatio

212 he Cobas AmpliPrep/Cobas TaqMan test and the Abbott RealTime test, are FDA cleared for use with EDTA

213 eligible for shorter treatment duration with Abbott RealTime versus 72% with the High Pure System.

214 However, using <12 IU/ml for Abbott RealTime, a similar proportion (74%) would be eli

215 [95% CI 23-38]) of 150 participants based on Abbott RealTime.

216 RNA by the High Pure System or <12 IU/ml by Abbott RealTime; however, 92% of the patients with undet

217 the Abbott TaqMan analyte-specific reagent (Abbott reverse transcription-PCR [RT-PCR]), Roche TaqMan

218 Abbott RT-PCR and Roche RT-PCR detected all 28 replicate

219 (1 through 4) were tested in the Bayer bDNA, Abbott RT-PCR, and Roche RT-PCR assays.

220 For Abbott RT-PCR, mean viral load values were 0.61 to 0.96

221 another weak-affinity fragment derived from Abbott's ABT-737 led to an improvement of the binding af

222 bination of the lipophilic indole portion of Abbott's first-generation PAF antagonist ABT-299 (2) wit

223 For diagnosis, we used Abbott's ligase chain reaction (LCR) on urine specimens

224 M), real-time PCR with molecular beacon, and Abbott's ligase chain reaction (LCx).

225 nti-HBsAg), in human serum was compared to a Abbott second-generation enzyme immunoassay (EIA 2.0).

226 re tested in multiple laboratories using the Abbott TaqMan analyte-specific reagent (Abbott reverse t

227 Comparison of plasma viral loads using the Abbott test and the Roche Amplicor Monitor test showed a

228 For plasma specimens, the Abbott test had a limit of detection of 2.3 log10 copies

229 s favorably with that for the less sensitive Abbott Test Pack RSV.

230 ., Cockeysville, Md.) and influenza A virus (Abbott Test Pack; Abbott Laboratories, Abbott Park, Ill.

231 In addition, the Abbott test viral loads correlated with the Digene Hybri

232 We compared the Abbott Toxo immunoglobulin G (IgG) and IgM IMx assays wi

233 gM, version 2, 93.3 and 97.3%, respectively; Abbott Toxo-M EIA, 100 and 84.2%, respectively; BioMerie

234 e-to-edge repair using the Mitraclip system (Abbott Vascular Devices, California, USA).

235 th Xience V everolimus-eluting stents (EES) (Abbott Vascular Devices, Santa Clara, California) at 1-y

236 ute of Neurological Disorders and Stroke and Abbott Vascular Solutions (formerly Guidant).

237 ute of Neurological Disorders and Stroke and Abbott Vascular Solutions.

238 occlusion patients treated with BRS (Absorb; Abbott Vascular) and second-generation drug-eluting sten

239 d artery stenting or carotid endarterectomy (Abbott Vascular).

240 d percutaneously using the MitraClip device (Abbott Vascular, Abbott Park, Illinois) and compare the

241 and XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Abbott Park, Illinois) in the RESOLUTE

242 ed post-approval study of MitraClip therapy (Abbott Vascular, Inc., Santa Clara, California).

243 Boston Scientific, Abbott Vascular, Medtronic, Cordis, Biosensors, The Medi

244 y and effectiveness of the MitraClip device (Abbott Vascular, Menlo Park, CA) is being evaluated in t

245 valve (MV) repair with the MitraClip device (Abbott Vascular, Menlo Park, California).

246 ith Absorb bioresorbable vascular scaffolds (Abbott Vascular, Santa Clara, CA).

247 imus-eluting bioresorbable scaffold (Absorb; Abbott Vascular, Santa Clara, CA, USA) or treatment with

248 imus-eluting bioresorbable scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) or treatment with

249 n everolimus-eluting metallic stent (Xience; Abbott Vascular, Santa Clara, CA, USA).

250 n everolimus-eluting metallic stent (Xience, Abbott Vascular, Santa Clara, CA, USA).

251 allic drug-eluting stent (DES) implantation (Abbott Vascular, Santa Clara, California) and determine

252 red the safety and efficacy of the XIENCE V (Abbott Vascular, Santa Clara, California) everolimus-elu

253 nd Xience V everolimus-eluting stents (EES) (Abbott Vascular, Santa Clara, California) following stri

254 patients who received the MitraClip device (Abbott Vascular, Santa Clara, California) for mitral reg

255 y and effectiveness of the MitraClip device (Abbott Vascular, Santa Clara, California) in patients wi

256 ong agreement (Cohen's kappa, 0.76 to 0.82), Abbott was more likely to detect HIV-1 RNA levels of >50